Long-term statin persistence is poor among high-risk patients with dyslipidemia: a real-world administrative claims analysis

Abstract Background A decade ago, statin persistence was < 50% after 1 year, and recent short-term analyses have revealed very little progress in improving statin persistence, even in patients with a prior cardiovascular (CV) event. Data on longer-term statin persistence are lacking. We measured...

Full description

Bibliographic Details
Main Authors: Peter P. Toth, Craig Granowitz, Michael Hull, Amy Anderson, Sephy Philip
Format: Article
Language:English
Published: BMC 2019-09-01
Series:Lipids in Health and Disease
Subjects:
Online Access:http://link.springer.com/article/10.1186/s12944-019-1099-z
id doaj-0a1f41617a5f409383e4b0c6c1c28308
record_format Article
spelling doaj-0a1f41617a5f409383e4b0c6c1c283082020-11-25T02:48:50ZengBMCLipids in Health and Disease1476-511X2019-09-0118111410.1186/s12944-019-1099-zLong-term statin persistence is poor among high-risk patients with dyslipidemia: a real-world administrative claims analysisPeter P. Toth0Craig Granowitz1Michael Hull2Amy Anderson3Sephy Philip4CGH Medical CenterAmarin Pharma IncOptumOptumAmarin Pharma IncAbstract Background A decade ago, statin persistence was < 50% after 1 year, and recent short-term analyses have revealed very little progress in improving statin persistence, even in patients with a prior cardiovascular (CV) event. Data on longer-term statin persistence are lacking. We measured long-term statin persistence in patients with high CV risk. Methods This retrospective administrative claims analysis of the Optum Research Database included patients aged ≥ 45 years with diabetes and/or atherosclerotic CV disease (ASCVD) who had a statin prescription filled in 2010. It included an elevated triglycerides (TG) cohort of patients with index date in 2010 and TG ≥ 150 mg/dL (n = 23,181) and a propensity-matched comparator cohort with TG < 150 mg/dL and high-density lipoprotein cholesterol > 40 mg/dL (n = 23,181). Both cohorts were followed for ≥ 6 months up to March 2016. Results The probability of remaining on a prescription fill for index statin therapy was 47% after 1 year and 19% after 5 years in both cohorts. Statin persistence was worse among women than men, and among younger versus older patients (P < 0.001 for all comparisons). After 5 years, the probability of remaining on a prescription fill for index statin was < 25% across all subgroups assessed including patients with and without baseline revascularization, heart failure, peripheral artery disease and renal disease. Similar results were observed in a subcohort analysis of patients with TG 200–499 mg/dL. Conclusions Long-term statin persistence after 5 years is alarmingly low (< 25%) and is a public health concern.http://link.springer.com/article/10.1186/s12944-019-1099-zStatinTriglyceridesPersistenceDiscontinuationAtherosclerotic cardiovascular diseaseDiabetes
collection DOAJ
language English
format Article
sources DOAJ
author Peter P. Toth
Craig Granowitz
Michael Hull
Amy Anderson
Sephy Philip
spellingShingle Peter P. Toth
Craig Granowitz
Michael Hull
Amy Anderson
Sephy Philip
Long-term statin persistence is poor among high-risk patients with dyslipidemia: a real-world administrative claims analysis
Lipids in Health and Disease
Statin
Triglycerides
Persistence
Discontinuation
Atherosclerotic cardiovascular disease
Diabetes
author_facet Peter P. Toth
Craig Granowitz
Michael Hull
Amy Anderson
Sephy Philip
author_sort Peter P. Toth
title Long-term statin persistence is poor among high-risk patients with dyslipidemia: a real-world administrative claims analysis
title_short Long-term statin persistence is poor among high-risk patients with dyslipidemia: a real-world administrative claims analysis
title_full Long-term statin persistence is poor among high-risk patients with dyslipidemia: a real-world administrative claims analysis
title_fullStr Long-term statin persistence is poor among high-risk patients with dyslipidemia: a real-world administrative claims analysis
title_full_unstemmed Long-term statin persistence is poor among high-risk patients with dyslipidemia: a real-world administrative claims analysis
title_sort long-term statin persistence is poor among high-risk patients with dyslipidemia: a real-world administrative claims analysis
publisher BMC
series Lipids in Health and Disease
issn 1476-511X
publishDate 2019-09-01
description Abstract Background A decade ago, statin persistence was < 50% after 1 year, and recent short-term analyses have revealed very little progress in improving statin persistence, even in patients with a prior cardiovascular (CV) event. Data on longer-term statin persistence are lacking. We measured long-term statin persistence in patients with high CV risk. Methods This retrospective administrative claims analysis of the Optum Research Database included patients aged ≥ 45 years with diabetes and/or atherosclerotic CV disease (ASCVD) who had a statin prescription filled in 2010. It included an elevated triglycerides (TG) cohort of patients with index date in 2010 and TG ≥ 150 mg/dL (n = 23,181) and a propensity-matched comparator cohort with TG < 150 mg/dL and high-density lipoprotein cholesterol > 40 mg/dL (n = 23,181). Both cohorts were followed for ≥ 6 months up to March 2016. Results The probability of remaining on a prescription fill for index statin therapy was 47% after 1 year and 19% after 5 years in both cohorts. Statin persistence was worse among women than men, and among younger versus older patients (P < 0.001 for all comparisons). After 5 years, the probability of remaining on a prescription fill for index statin was < 25% across all subgroups assessed including patients with and without baseline revascularization, heart failure, peripheral artery disease and renal disease. Similar results were observed in a subcohort analysis of patients with TG 200–499 mg/dL. Conclusions Long-term statin persistence after 5 years is alarmingly low (< 25%) and is a public health concern.
topic Statin
Triglycerides
Persistence
Discontinuation
Atherosclerotic cardiovascular disease
Diabetes
url http://link.springer.com/article/10.1186/s12944-019-1099-z
work_keys_str_mv AT peterptoth longtermstatinpersistenceispooramonghighriskpatientswithdyslipidemiaarealworldadministrativeclaimsanalysis
AT craiggranowitz longtermstatinpersistenceispooramonghighriskpatientswithdyslipidemiaarealworldadministrativeclaimsanalysis
AT michaelhull longtermstatinpersistenceispooramonghighriskpatientswithdyslipidemiaarealworldadministrativeclaimsanalysis
AT amyanderson longtermstatinpersistenceispooramonghighriskpatientswithdyslipidemiaarealworldadministrativeclaimsanalysis
AT sephyphilip longtermstatinpersistenceispooramonghighriskpatientswithdyslipidemiaarealworldadministrativeclaimsanalysis
_version_ 1724746342627016704